首页|期刊导航|Cancer Biology & Medicine|IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses

Yuli Ruan Mengde Shi Yue Ma Bojun Wang Ming Ma Tianjiao Dang Yanqiao Zhang Chao Liu

Cancer Biology & Medicine2025，Vol.22Issue(11)：P.1372-1376,5.

Cancer Biology & Medicine2025，Vol.22Issue(11)：P.1372-1376,5.DOI:10.20892/j.issn.2095-3941.2025.0344

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses

Yuli Ruan ¹Mengde Shi ¹Yue Ma ¹Bojun Wang ¹Ming Ma ²Tianjiao Dang ²Yanqiao Zhang ³Chao Liu³

作者信息

1. Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China Clinical Research Center for Colorectal Cancer in Heilongjiang,Harbin 150001,China Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China
2. Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China
3. Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China Clinical Research Center for Colorectal Cancer in Heilongjiang,Harbin 150001,China Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China(Harbin Medical University),Ministry of Education,Harbin 150001,China
折叠

摘要

关键词

Immune checkpoint inhibitors/immune-related cutaneous adverse events/psoriasiform rash/IL-17A/secukinumab

分类

医药卫生

引用本文复制引用

Yuli Ruan,Mengde Shi,Yue Ma,Bojun Wang,Ming Ma,Tianjiao Dang,Yanqiao Zhang,Chao Liu..IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses[J].Cancer Biology & Medicine,2025,22(11):P.1372-1376,5.

基金项目

supported by grants from the National Natural Science Foundation of China(Nos.82373372 and U22A20330) （Nos.82373372 and U22A20330）

Key Project of Research and Development Plan in Heilongjiang Province(Nos.2022ZX06C01 and JD2023SJ40) （Nos.2022ZX06C01 and JD2023SJ40）

National Cancer Center Climbing Fund(No.NCC201908A03) （No.NCC201908A03）

Beijing Xisike Clinical Oncology Research Foundation(No.Y-HR2020MS-0900). （No.Y-HR2020MS-0900）

Cancer Biology & Medicine

ISSN：2095-3941

访问量0

下载量0

段落导航